TommyBoyTrader

[Covid19freak]

KZIA $0.35 -Phase 3 data imminent for cancer drug expected in early Q1 - market cap at laughable 9 million IF results are positive this low floater going to explode

A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is completed, with final data expected in first half of CY2024. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma, with several of these having reported encouraging interim data.